乳腺癌17号染色体多体的临床病理意义

Cfinicopathologic significance of chromosome 17 polysomy in breast cancer

目的探讨乳腺癌17号染色体多体异常的临床病理学意义。方法回顾性分析200例乳腺癌荧光原位杂交结果，并分析17号染色体多体与年龄、核异型性、淋巴结转移以及HER2基因扩增、HER2蛋白表达的关系。结果200例乳腺癌患者中表现为17号染色体多体异常的52例（26．0％），均为浸润性导管癌；占180例浸润性导管癌的52．8％。17号染色体多体与HER2基因扩增和HER2蛋白表达有关（均P=0．000），并且多体伴HER2基因扩增时也与HER2蛋白表达有关（P=0．001）。多体和（或）多体伴HER2基因扩增都与乳腺癌癌细胞的高度异型性（P=0．010或P=0．012）及淋巴结转移有关（P=0．009或P=0．002）。17号染色体多体或多体伴HER2基因扩增与乳腺癌患者的年龄无关（P=0．415或P=1．000）。结论17号染色体多体可能与乳腺癌患者的预后不良有关。

Objective To investigate the clinicopathological significance of chromosome 17 polysomy in breast cancer. Methods Retrospective study of 200 cases of breast cancer including 106 cases of invasive ductal carcinoma and 94 cases of in-situ carcinoma was performed by fluorescence in-situ hybridization （FISH） to explore the relationship between chromosome 17 polysomy and age, nuclear atypia, lymphatic metastasis, HER2 gene amplification and HER2 protein expression. Results Twenty-six percent （52/200） of chromosome 17 polysomy was detected in 200 cases of breast ductal carcinoma, all of which were invasive ductal carcinoma. Overall 52. 8% （52/180） of invasive ductal carcinoma cases showed Chromosome 17 polysomy, which was correlated to HER2 gene amplification （P = 0. 000）and HER-2 protein expression（P = 0. 000 ）, and to HER2 expression combined with HER2 gene amplification （ P = 0. 001 ）. Chromosome 17 polysomy with or without HER2 gene amplification was also associated with high-grade nuclear atypia（P =0. 012 or P = 0. 010） and lymphatic metastasis （ P = 0. 002 or P = 0. 009）. However, chromosome 17 polysomy with or without HER2 gene amplification was not correlative with the age of patients （P = 1. 000 or P = 0. 415）. Conclusion Chromosome 17 polysomy may be related to the nuclear atypia, metastasis, HER2 gene amplification of invasive ductal carcinoma and thus a worse prognosis of the patients.